No label defined (Q30639)
Jump to navigation
Jump to search
No description defined
- Incidence of High Risk and Malignant Pathological Findings in Transgender and Gender Diverse Individuals Undergoing Gender-Affirming Mastectomy.
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
No description defined |
|
Statements
Concrete, data-driven guidelines for breast cancer screening among the transgender and gender diverse (TGD) population is lacking. (English)
BACKGROUND (English)
© 2024. The Author(s). (English)
2024
The present study evaluates possible associations of gender-affirming hormone therapy (GAHT) on incidental breast pathology findings in trans-masculine patients to inform decision making about breast cancer screening. (English)
BACKGROUND (English)
© 2024. The Author(s). (English)
2024
This was a retrospective cohort study of patients who had gender-affirming mastectomy or breast reduction at a single center from July 2019 to February 2024. (English)
PATIENTS AND METHODS (English)
© 2024. The Author(s). (English)
2024
A total of 865 patients met the inclusion criteria. (English)
PATIENTS AND METHODS (English)
© 2024. The Author(s). (English)
2024
Gender-affirming testosterone therapy and length of exposure were evaluated to seek differences in post-operative pathology findings. (English)
PATIENTS AND METHODS (English)
© 2024. The Author(s). (English)
2024
The median age at the time of surgery was 27 years [interquartile range (IQR) 21-30]. (English)
RESULTS (English)
© 2024. The Author(s). (English)
2024
Most participants identified as female to male (658, 75.6%). (English)
RESULTS (English)
© 2024. The Author(s). (English)
2024
A significant portion of the participants (688, 79.2%) were undergoing testosterone therapy at the time of surgery, with the median duration of testosterone use prior to surgery being 14 months (IQR 4-29). (English)
RESULTS (English)
© 2024. The Author(s). (English)
2024
High risk or malignant findings were noted in pathology results for 12 of 1730 breasts (0.7%). (English)
RESULTS (English)
© 2024. The Author(s). (English)
2024
Ordered logistic regression found that duration of testosterone therapy was not associated with increasing severity of incidental breast pathology. (English)
RESULTS (English)
© 2024. The Author(s). (English)
2024
Additionally, patients under 25 years of age were 70% less likely to have any incidental finding on pathological evaluation than older patients [odds ratio (OR) 0.3, p < 0.01, confidence interval (CI) 0.18-0.50]. (English)
RESULTS (English)
© 2024. The Author(s). (English)
2024
The present study found that patients undergoing GAHT should not be screened for breast cancer with increased frequency compared with cis-gender women. (English)
CONCLUSIONS (English)
© 2024. The Author(s). (English)
2024
Additionally, it may be appropriate for trans women under the age of 25 with normal breast cancer risk to forego pathological breast tissue examination. (English)
CONCLUSIONS (English)
© 2024. The Author(s). (English)
2024
Rachel L (English)
McCaffrey (English)
RL
Andrew J (English)
James (English)
AJ
Ricardo A (English)
Torres-Guzman (English)
RA
Jamin K (English)
Addae (English)
JK
Lauren E (English)
Sullivan (English)
LE
Elianna (English)
Dash (English)
E
Hanna (English)
Slutsky (English)
H
Zoe R (English)
Finer (English)
ZR
Patrick E (English)
Assi (English)
PE
Salam (English)
Al-Kassis (English)
S
13 October 2024
11 October 2024